Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory, Open Label, Single-arm Study to Evaluate the Effect of Eligard® 6-month on Biomarkers of Disease in Patients With Metastatic Prostate Cancer

NCT01933022 is registered in ClinicalTrials.gov with Astellas Pharma Europe Ltd. as lead sponsor.

NCT NCT01933022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01933022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory, Open Label, Single-arm Study to Evaluate the Effect of Eligard® 6-month on Biomarkers of Disease in Patients With Metastatic Prostate Cancer
Lead sponsor
Astellas Pharma Europe Ltd.
Phase
Phase 4
Overall status
Terminated
Start date
August 31, 2014
Completion date
August 31, 2015
Enrollment
1 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate cancer